OakChart

Rockwell Medical Inc

RMTIHealthcare·Drug Manufacturers - Specialty & Generic·USA·Nano·NASD·Nov 11 • 10:59 AM ET

7.02-0.29 (-3.97%)
2026-11-11 17:02 CET
Market cap
29.46 USD m
Revenue, TTM
69.39 USD m
Net income, TTM
-5.24 USD m
Free cash flow, TTM
1.54 USD m
EPS diluted, TTM
-1.37
P/E
-
Compare

Price

RMTI against its 20, 50 and 200-day averages
2050200missearnings
6.008.0010.0072K145KMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26RMTIclose 7.0220-day 7.3550-day 7.83200-day 8.097.0252w low

45.6% under the 52-week high of 12.90 on 20 Jan 2026. 52-week low 4.89 on 2 Jul 2026. Last 15 sessions, 25.6% high to low

Profile

RMTI
52-week range, 27% of the way up
4.8912.90

Rockwell Medical, Inc. is a biopharmaceutical company, which engages in the development of treatment for anemia, kidney disease, iron deficiency, and hemodialysis. Its products include Triferic, CitraPure, RenalPure and SteriLyte. The company was founded by Robert L. Chioini on October 25, 1996 and is headquartered in Wixom, MI.

Employees157
IPOJan 27, 1998
Beta1.72
ATR, 14d0.50
Rel volume0.30
Short float1.05%
Insider own16.37%
Inst own8.46%

Snapshot

6 groups

Valuation

Index-
Market Cap28.29M
Enterprise Value17.42M
Income-5.24M
Sales69.39M
Book/sh8.83
Cash/sh6.15
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees157
IPOJan 27, 1998

Ratios

P/E-
Forward P/E-
PEG-
P/S0.41
P/B0.79
P/C1.14
P/FCF18.37
EV/EBITDA-
EV/Sales0.25
Quick Ratio3.00
Current Ratio3.25
Debt/Eq0.40
LT Debt/Eq0.29
Option/ShortNo / Yes

Earnings

EPS (ttm)-1.37
EPS next Y-0.20
EPS next Q-0.18
EPS this Y32.67%
EPS next Y79.70%
EPS next 5Y48.37%
EPS past 3/5Y56.86% 49.20%
Sales past 3/5Y-1.65% 2.17%
EPS Y/Y TTM-109.07%
Sales Y/Y TTM-21.12%
EPS Q/Q22.91%
Sales Q/Q10.63%
EarningsNov 12 BMO
EPS/Sales Surpr.-44.68% -0.22%

Ownership

Insider Own16.37%
Insider Trans-0.15%
Inst Own8.46%
Inst Trans-1.60%
ROA-9.32%
ROE-15.53%
ROIC-11.21%
Gross Margin17.71%
Oper. Margin-6.52%
Profit Margin-7.55%
SMA20-4.48%
SMA50-10.38%
SMA200-13.23%
Trades-

Technical

Shs Outstand3.97M
Shs Float3.37M
Short Float1.05%
Short Ratio1.37
Short Interest0.04M
52W High12.90 -45.58%
52W Low4.89 43.71%
Volatility6.92% 6.87%
ATR (14)0.50
RSI (14)42.32
Beta1.72
Rel Volume0.30
Avg Volume25.86K
Volume2,118

Performance

Perf Week-12.80%
Perf Month-10.57%
Perf Quarter-10.29%
Perf Half Y-12.37%
Perf YTD-15.78%
Perf Year-33.14%
Perf 3Y-61.85%
Perf 5Y-88.12%
Perf 10Y-98.83%
Recom1.00
Target Price20.00
Prev Close7.31
Price7.02
Change %-3.97%

Analyst ratings

latest 10 of 18
DateActionAnalystRating changeTargetImplied
Nov 14, 2024InitiatedRRodman & RenshawBuy$5-28.8%
Jun 24, 2019InitiatedPPiper JaffrayOverweight$10+42.5%
May 13, 2019InitiatedHH.C. WainwrightBuy$11+56.7%
Nov 08, 2016DowngradeBBofA/MerrillNeutral → Underperform
Mar 01, 2016DowngradeSStifelBuy → Hold
Aug 13, 2015InitiatedMMorgan StanleyUnderweight$7-0.3%
Jan 27, 2015ReiteratedOOppenheimerOutperform$24 → $26+270.4%
Jan 07, 2015InitiatedOOppenheimerOutperform$24+241.9%
Aug 14, 2014InitiatedFFBR CapitalUnderperform$6-14.5%
Dec 19, 2013InitiatedCChardan Capital MarketsBuy$22+213.4%

Peers

Mkt cap
TickerCompanyMkt cap
AKBAAkebia Therapeutics Inc144.36M
TLPHTalphera Inc55.28M
FMSFresenius Medical Care AG ADR11.70B
CRMDCorMedix Inc416.62M
NEPHNephros Inc35.27M
OMOutset Medical Inc80.68M
UNCYUnicycive Therapeutics Inc103.90M
ARDXArdelyx Inc772.94M
DVADaVita Inc11.29B
ICUIICU Medical Inc4.48B

Insider trading

8 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Strobeck MarkPresident and CEOOct 01 '26Sale8.421,0008,42061,349Oct 05 04:03 PM
Strobeck MarkOfficerOct 01 '26Proposed Sale8.401,0008,400Oct 01 03:29 PM
Hunter HeatherChief Operating OfficerJan 02 '26Sale0.842,8682,396132,523Jan 05 04:15 PM
Neri JesseSVP and CFOJan 02 '26Sale0.84886740124,842Jan 05 04:13 PM
Neri JesseOfficerJan 02 '26Proposed Sale0.80886712Jan 05 09:38 AM
Hunter HeatherOfficerJan 02 '26Proposed Sale0.812,8682,318Jan 02 04:40 PM
COOPER JOHN GDirectorNov 18 '25Sale0.875,0794,419140,372Nov 18 04:26 PM
COOPER JOHN GDirectorNov 18 '25Proposed Sale0.905,0794,572Nov 18 09:54 AM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B

News

latest 14 of 206
  • Rockwell Medical's Q3 Must Prove Growth Can Outlast The Easy DaVita Comparison (Earnings Whispers)
  • Rockwell Medical stock surges on $125M Vantive acquisition deal (Investing.com) +17.08%
  • Vantive Announces Agreement to Divest Majority of Hemodialysis Assets and Associated Operations to Rockwell Medical (PR Newswire)
  • Rockwell Medical Announces Transformational Global Hemodialysis Acquisition (Business Wire)
  • Rockwell Medical to Release Third Quarter 2026 Results on Thursday, November 12, 2026 (Business Wire)
  • Loading…
  • Rockwell Medical to Exhibit at ASN Kidney Week 2026 (Business Wire)
  • Rockwell Medical Ranked No. 16 on the 2026 Fortune 'Best Workplaces in Manufacturing & Production' List (Business Wire) +7.45%
  • Rockwell Medical Inc (RMTI) (Q2 2026) Earnings Call Highlights: Revenue Up 11% and Cash Flow ... (GuruFocus.com) -5.30%
  • Rockwell Medical: Q2 Earnings Snapshot (Associated Press)
  • Rockwell Medical Announces Second Quarter 2026 Results (Business Wire)
  • Rockwell Medical Advances Quality and Regulatory Leadership (Business Wire)
  • Rockwell Medical Regains Compliance with Nasdaq Listing Requirements (Business Wire)
  • Rockwell Medical to Release Second Quarter 2026 Results on Thursday, August 13, 2026 (Business Wire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-12--0.180--18.222
2026Q22026-08-13-0.340-0.235-0.34017.7817.822
2026Q12026-05-07-0.400-0.250-0.40717.3417.952
2025Q42026-03-26-0.1000.200-0.14118.3518.602
2025Q32025-11-12-0.500-0.450-0.48715.9316.242
2025Q22025-08-14-0.500-0.500-0.43516.0716.332
2025Q12025-05-12-0.400-0.500-0.44418.9117.462
2024Q42025-03-20-0.2000.033-0.23024.6723.503
2024Q32024-11-120.5000.1000.44128.3126.502
2024Q22024-08-080.100-0.3500.08925.8022.912
2024Q12024-05-14-0.600-0.400-0.59022.6821.702
2023Q42024-03-21-0.500-0.700-0.52822.0922.632
2023Q32023-11-14-0.700-1.050-0.68023.7722.852
2023Q22023-08-14-1.800-1.200-1.78718.0818.081
2023Q12023-05-15-1.000-1.650-0.95319.6719.122
2022Q42023-03-30-2.000-3.900-2.04319.3116.302

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2018FY-67.100-62.700-66.89863.3962.63
2019FY-61.600-63.067-61.62461.3062.03
2020FY-45.100-43.450-44.93362.2062.73
2021FY-38.500-37.400-38.32261.9064.25
2022FY-18.900-21.200-18.93172.8169.80
2023FY-3.600-4.000-3.61883.6184.15
2024FY-0.3000.100-0.252101.49100.32
2025FY-1.500-1.150-1.50069.2669.51
2026FY--1.010--72.34
2027FY--0.205--78.15
2028FY--0.206--81.44
2029FY-1.400--81.60

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-11-0320018.2218.2018.24
2026Q3S2026-09-1020018.2218.2018.24
2026Q3S2026-08-1820018.2718.2418.30
2026Q3S2026-08-1720018.2718.2418.30
2026Q3S2026-08-1610018.3018.3018.30
2026Q3S2026-08-1320018.2718.2418.30
2026Q3S2026-07-2220018.2718.2418.30
2026Q3S2026-07-0820118.2718.2418.30
2026Q3S2026-06-0920118.2818.2418.32
2026Q3S2026-05-0820218.2818.2418.32
2026Q3S2026-05-0720118.5218.2418.80
2026Q3S2026-04-0820118.5218.2418.80
2026Q3S2026-03-2720218.5218.2418.80
2026Q3S2026-03-2620218.5718.2418.90

Estimate history

EPS, annual-55.835-66.898-61.624-44.933-38.322-18.931-3.618-0.252-1.52-1.3696
Period201720182019202020212022202320242025TTM
EPS, quarterly0.0890.441-0.23-0.444-0.435-0.487-0.141-0.407-0.335
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual57.363.38961.30362.19761.93172.8183.612101.48969.25869.39
Period201720182019202020212022202320242025TTM
Sales, quarterly25.83228.31624.66518.91416.07115.92718.34517.33617.78
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual0.4710.5180.5940.8510.8541.2162.9133.4063.9413.972
Period201720182019202020212022202320242025MRQ
Shares, quarterly3.1033.2323.4063.4263.4433.9413.9413.9473.972
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue69.3969.26101.4983.6172.8161.9362.2061.3063.39
Cost of Goods Sold Incl. D&A57.1057.5684.0074.9168.7364.3559.4758.4664.97
Gross Profit12.2911.7017.488.704.08-2.422.732.84-1.58
Selling, General and Administrative Excl. Other16.8116.3916.8815.3720.8627.9231.1436.9329.82
Research and Development-0.000.021.113.126.837.096.896.74
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-4.52-4.690.61-6.67-16.78-30.34-28.42-34.10-31.41
Interest Expense1.131.121.252.301.942.361.88-0.00
Unusual Expense0.000.000.000.000.000.000.000.431.03
Net Income Before Taxes-5.08-5.31-0.48-8.44-18.68-32.67-30.89-34.13-32.13
Income Taxes0.000.000.000.000.000.000.000.000.00
Consolidated Net Income-5.08-5.31-0.48-8.44-18.68-32.67-30.89-34.13-32.13
Net Income From Continuing Operations-5.08-5.31-0.48-8.44-18.68-32.67-30.89-34.13-32.13
Net Income-5.24-5.47-0.78-8.44-18.68-32.67-30.89-34.13-32.13
EPS (Recurring)-1.32-1.52-0.25-3.62-18.93-38.32-44.93-61.08-65.40
EPS (Basic, Before Extraordinaries)-1.37-1.52-0.25-3.62-18.93-38.32-44.93-61.62-66.90
EPS (Diluted)-1.37-1.52-0.25-3.62-18.93-38.32-44.93-61.62-66.90
EBITDA-2.43-2.502.79-5.23-14.19-27.82-26.13-31.44-30.76
Non-Operating Income (Expense)0.570.500.170.530.040.02-0.590.400.31
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense1.871.821.290.930.320.940.474.951.59
Price To Sales Ratio0.310.430.620.530.140.621.232.421.88
Gross Margin17.7116.8917.2310.415.60-3.914.384.63-2.50
Operating Margin-6.52-6.770.60-7.98-23.05-48.98-45.69-55.62-49.55
Net Margin-7.55-7.89-0.77-10.09-25.65-52.76-49.66-55.67-50.68
Shares Outstanding3.973.943.412.911.220.850.850.590.52
Market Capitalization29.4629.4669.4853.8511.3238.5394.51159.52128.90

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue17.7817.3418.3415.9316.0718.9124.6628.32
Cost of Goods Sold Incl. D&A14.5414.4414.4713.6513.5715.8721.0322.08
Gross Profit3.242.903.882.272.503.043.636.24
Selling, General and Administrative Excl. Other4.304.384.283.863.854.404.154.30
Research and Development0.04-0.000.000.000.000.000.00
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-1.06-1.48-0.40-1.58-1.35-1.36-0.521.94
Interest Expense0.280.280.290.280.280.280.290.30
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-1.17-1.60-0.55-1.75-1.49-1.51-0.761.66
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-1.17-1.60-0.55-1.75-1.49-1.51-0.761.43
Net Income From Continuing Operations-1.17-1.60-0.55-1.75-1.49-1.51-0.761.43
Net Income-1.33-1.60-0.55-1.75-1.49-1.51-0.761.43
EPS (Recurring)-0.34-0.41-0.14-0.49-0.43-0.44-0.230.44
EPS (Basic, Before Extraordinaries)-0.34-0.41-0.14-0.49-0.43-0.44-0.230.45
EPS (Diluted)-0.34-0.41-0.14-0.49-0.43-0.44-0.230.44
EBITDA-0.57-0.970.15-1.04-0.79-0.820.022.48
Non-Operating Income (Expense)0.170.160.130.120.130.120.050.03
Other After Tax Adjustments0.000.000.000.000.000.000.00-0.23
Stock Option Compensation Expense0.400.480.460.530.380.450.380.32
Price To Sales Ratio0.310.520.470.570.330.390.661.30
Gross Margin18.2416.7121.1314.2715.5716.0814.7222.03
Operating Margin-5.97-8.54-2.17-9.95-8.39-7.19-2.106.84
Net Margin-7.46-9.26-3.02-11.01-9.28-8.01-3.065.05
Shares Outstanding3.973.953.943.943.443.433.413.23
Market Capitalization29.4635.2532.8447.2929.2038.7169.48128.31

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments25.0021.6010.9421.4922.4458.6826.0433.5333.06
Short Term Receivables8.148.2910.906.265.914.174.207.356.36
Inventories3.425.785.875.814.083.913.654.047.64
Other Current Assets1.601.361.061.752.862.712.981.901.78
Total Current Assets38.1637.0328.7735.3135.2969.4736.8746.8348.83
Net Property, Plant & Equipment7.8510.3411.028.6110.225.555.652.642.55
Total Investments and Advances0.000.000.000.000.000.000.000.000.00
Intangible Assets10.5811.1311.680.920.920.920.920.920.92
Other Assets0.560.710.701.802.141.800.882.176.48
Total Assets57.1559.2152.1746.6348.5777.7544.3252.5658.78
Short Term Debt Incl. Current Port. of LT Debt1.892.432.184.149.821.172.260.000.00
Accounts Payable2.002.874.524.053.744.163.024.494.22
Other Current Liabilities5.698.799.949.507.417.477.108.714.92
Total Current Liabilities9.5814.0916.6417.6920.9712.7912.3713.209.14
Long Term Debt10.5811.1011.2612.2219.0722.771.780.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities0.001.432.992.616.008.029.8412.0816.72
Total Liabilities20.1626.6230.8832.5346.0443.5824.0025.2825.87
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity36.9832.5921.2914.112.5434.1720.3227.2832.91
Total Shareholders Equity36.9832.5921.2914.112.5434.1720.3227.2832.91
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity36.9832.5921.2914.112.5434.1720.3227.2832.91
Total Liabilities & Stockholders Equity57.1559.2152.1746.6348.5777.7544.3252.5658.78
Book Value Per Share9.389.577.3111.602.9740.1734.1952.6169.94
Tangible Book Value Per Share6.706.303.3010.841.8939.0932.6450.8367.97
Full-Time Employees157244237253300300299269300
Price to Book Ratio0.832.132.500.7015.202.777.854.737.39
Return on Assets-9.13-0.86-17.08-39.24-51.73-50.61-70.46-57.71-36.53
Return on Equity-15.28-1.78-47.68-224.49-178.04-113.38-143.41-106.75-60.37
Return on Invested Capital-11.17-1.10-25.93-70.94-151.21-54.25-154.42-117.78-78.76
Quick Ratio3.632.221.381.671.495.122.693.244.51
Current Ratio3.982.631.732.001.685.432.983.555.34

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-5.08-5.31-0.48-8.44-18.68-32.67-30.89-34.13-32.13
Depreciation2.092.192.181.442.592.522.292.650.65
Other Funds (Non Cash)3.814.084.034.831.281.471.926.2014.49
Funds from Operations0.810.955.73-2.17-14.81-28.69-26.68-25.28-16.99
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital2.08-1.61-1.53-7.24-2.61-4.84-2.96-1.98-3.43
Cash from Operating Activities2.90-0.664.20-9.41-17.41-33.53-29.64-27.25-20.42
Capital Expenditures-1.36-0.54-1.01-12.64-0.28-0.52-1.05-1.34-0.99
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00-
Sale of Fixed Assets and Businesses0.170.000.000.000.000.000.000.000.00
Purchase or Sale of Investments-7.87-8.00-3.859.60-2.120.834.26-3.4113.72
Purchase of Investments-32.47-24.20-5.86-5.70-21.30-26.06-29.31-41.68-20.18
Sale Or Maturity of Investments24.6016.202.0015.3019.1826.8933.5638.2733.90
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-9.05-8.54-4.87-3.04-2.400.313.21-4.7512.72
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock7.827.8210.1814.8629.820.1142.9422.2322.00
Repurchase of Common Pref Stock0.000.000.000.000.000.000.00-0.280.00
Sale of Common Pref Stock7.827.8210.1814.8629.820.1142.9422.5122.00
Proceedsfrom Stock Options7.827.8210.1814.8629.820.1142.9422.3621.94
Issuance or Reduction of Debt, Net-1.13-1.19-0.65-2.99-13.19-2.2820.39-1.150.00
Change in Long Term Debt-0.47-0.530.00-2.00-11.75-0.7521.160.000.00
Issuance of Long Term Debt0.000.000.000.000.000.0021.160.000.00
Reduction of Long Term Debt-0.47-0.530.00-2.00-11.75-0.750.000.000.00
Net Financing Active Other Cash Flow-2.50-2.37-1.630.000.00-0.01-0.020.000.00
Other Financing Activities Uses-2.50-2.37-1.630.000.00-0.01-0.020.000.00
Cash from Financing Activities4.194.257.3511.3416.63-2.1863.3221.0822.00
Exchange Rate Effect-0.00-0.01-0.00-----
Net Change in Cash-1.96-4.956.68-1.12-3.18-35.4036.89-10.9214.31
Free Cash Flow1.54-1.203.19-22.06-17.70-34.06-30.69-28.59-21.41
Preferred Dividends (Cash Flow)---0.000.000.000.000.000.00
Price to Free Cash Flow14.15-19.86------
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments24.8023.8925.0023.7118.4217.33
Short Term Receivables8.308.828.148.338.089.67
Inventories2.823.063.423.964.165.04
Other Current Assets0.441.171.601.510.940.99
Total Current Assets36.3636.9438.1637.5131.6133.03
Net Property, Plant & Equipment9.319.487.858.709.609.42
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets10.3010.4410.5810.7110.8510.99
Other Assets0.560.560.560.560.560.52
Total Assets56.5357.4257.1557.4952.6253.96
Short Term Debt Incl. Current Port. of LT Debt3.672.691.892.242.742.13
Accounts Payable3.183.452.001.521.501.93
Other Current Liabilities4.333.735.695.826.717.15
Total Current Liabilities11.179.879.589.5810.9511.21
Long Term Debt10.2711.7010.5810.8811.2710.73
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.50
Total Liabilities21.4421.5720.1620.4722.2222.44
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity35.0935.8636.9837.0230.4131.52
Total Shareholders Equity35.0935.8636.9837.0230.4131.52
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity35.0935.8636.9837.0230.4131.52
Total Liabilities & Stockholders Equity56.5357.4257.1557.4952.6253.96
Book Value Per Share8.839.089.389.398.839.20
Tangible Book Value Per Share6.246.446.706.685.685.99
Full-Time Employees--157---
Price to Book Ratio0.830.980.891.280.961.23
Return on Assets-9.32-9.70-9.13-9.63-4.41-1.06
Return on Equity-15.53-16.04-15.28-16.67-8.65-2.12
Return on Invested Capital-2.58-3.38-1.16-3.66-3.58-3.59
Quick Ratio3.003.433.633.502.512.50
Current Ratio3.253.743.983.922.892.95

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-1.17-1.60-0.55-1.75-1.49-1.51
Depreciation0.490.510.550.540.560.54
Other Funds (Non Cash)0.801.140.871.000.981.23
Funds from Operations0.120.040.86-0.210.050.25
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital1.96-0.211.43-1.101.79-3.74
Cash from Operating Activities2.08-0.172.29-1.311.84-3.49
Capital Expenditures-0.62-0.42-0.09-0.23-0.16-0.06
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.170.000.000.000.00
Purchase or Sale of Investments0.130.13-4.04-4.080.060.06
Purchase of Investments-7.07-7.07-11.24-7.08-2.94-2.94
Sale Or Maturity of Investments7.207.207.203.003.003.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-0.49-0.12-4.13-4.31-0.10-0.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)-0.00-0.000.000.00
Change in Capital Stock0.000.000.007.820.000.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.000.000.007.820.000.00
Proceedsfrom Stock Options0.000.000.007.820.000.00
Issuance or Reduction of Debt, Net-0.18-0.31-0.31-0.32-0.21-0.35
Change in Long Term Debt-0.12-0.12-0.11-0.12-0.15-0.15
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt-0.12-0.12-0.11-0.12-0.15-0.15
Net Financing Active Other Cash Flow-0.50-0.50-0.75-0.75-0.43-0.44
Other Financing Activities Uses-0.50-0.50-0.75-0.75-0.43-0.44
Cash from Financing Activities-0.68-0.81-1.066.74-0.65-0.78
Exchange Rate Effect--0.000.00--
Net Change in Cash0.91-1.10-2.901.131.09-4.27
Free Cash Flow1.46-0.592.21-1.541.68-3.55
Price to Free Cash Flow14.1520.04--10.8417.84

Revenue breakdown

Concentrate Products2024: 101.44M
Drug2024: 46.00K
Total Pharmaceutical Preparations revenue2025: 69.26M
Non-US2024: 9.23M 2025: 8.90M
United States2024: 92.26M 2025: 60.36M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-301.05%0.0M3.4M26.18K
2026-10-152.08%0.1M3.4M28.00K
2026-09-302.10%0.1M3.4M29.72K
2026-09-152.67%0.1M3.4M33.44K
2026-08-312.76%0.1M3.4M36.55K
2026-08-142.61%0.1M3.4M36.59K
2026-07-312.99%0.1M3.3M35.91K
2026-07-152.60%0.1M3.3M33.66K
2026-06-302.30%0.1M3.5M29.07K
2026-06-152.11%0.1M3.5M28.22K
2026-05-291.10%0.0M3.5M26.07K
2026-05-151.44%0.0M3.4M26.26K
2026-04-301.13%0.0M3.4M25.88K
2026-04-152.90%0.1M3.4M70.94K
2026-03-312.18%0.1M3.4M71.60K
2026-03-132.69%0.1M3.4M70.18K
2026-02-272.50%0.1M3.4M68.11K
2026-02-132.40%0.1M3.4M68.17K
2026-01-302.01%0.1M3.4M71.36K
2026-01-151.70%0.1M3.4M30.10K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-038-KCurrent report2026-11-02SEC
2026-10-054Statement of changes in beneficial ownership of securities2026-10-01SEC
2026-10-01144Filing for proposed sale of securities under Rule 144.SEC
2026-08-138-KCurrent report2026-08-13SEC
2026-08-1310-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-138-KCurrent report2026-08-13SEC
2026-07-208-KCurrent report2026-07-20SEC
2026-07-064Statement of changes in beneficial ownership of securities2026-07-01SEC
2026-07-064Statement of changes in beneficial ownership of securities2026-07-01SEC
2026-07-064Statement of changes in beneficial ownership of securities2026-07-01SEC
2026-07-064Statement of changes in beneficial ownership of securities2026-07-01SEC
2026-07-064Statement of changes in beneficial ownership of securities2026-07-01SEC
2026-07-064Statement of changes in beneficial ownership of securities2026-07-01SEC
2026-07-064Statement of changes in beneficial ownership of securities2026-07-01SEC
2026-07-064Statement of changes in beneficial ownership of securities2026-07-01SEC
2026-07-064Statement of changes in beneficial ownership of securities2026-07-01SEC
2026-07-064Statement of changes in beneficial ownership of securities2026-07-01SEC
2026-06-298-KCurrent report2026-06-24SEC
2026-06-158-KCurrent report2026-06-12SEC
2026-05-11DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-05-088-KCurrent report2026-05-08SEC
2026-05-078-KCurrent report2026-05-07SEC
2026-05-0710-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-078-KCurrent report2026-05-07SEC
2026-04-30DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-04-30SEC
2026-04-30ARSAnnual report to security holders. 2025-12-31SEC
2026-04-20PRE 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-04-20SEC
2026-04-174/A2025-05-20SEC
2026-04-174/A2025-05-20SEC
2026-04-174/A2025-05-20SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-10008.42K1
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-01003.14K2
2025-120000
2025-11004.42K1

Institutional holders

Manager% owned
VANGUARD CAPITAL MANAGEMENT LLC31.16%
RENAISSANCE TECHNOLOGIES LLC9.11%
JANE STREET GROUP, LLC6.21%
VANGUARD FIDUCIARY TRUST CO5.89%
Wealthspire Advisors, LLC3.85%
BlackRock, Inc.3.67%
STATE STREET CORP2.56%
NORTHERN TRUST CORP2.33%
GSA CAPITAL PARTNERS LLP1.77%
PANAGORA ASSET MANAGEMENT INC1.76%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND21.41%
VANGUARD EXTENDED MARKET INDEX FUND9.10%
VANGUARD INSTITUTIONAL TOTAL STOCK MARKET INDEX FUND0.65%
Fidelity Extended Market Index Fund0.49%
Fidelity Total Market Index Fund0.13%
Fidelity Series Total Market Index Fund0.12%
Fidelity Nasdaq Composite Index Fund0.05%
Blackstone Alternative Multi-Strategy Fund-0.09%

OakChart. RMTI. Cached 15 minutes.